High pathologic complete remission rate with liposome-encapsulated doxorubicin plus paclitaxel plus trastuzumab as primary treatment in HER-2 positive operable breast cancer: clinical experience

被引：0
|
作者：
Gavila, J. [1 ]
Guerrero-Zotano, A. [1 ]
Climent, M. A. [1 ]
Blanch, S. [1 ]
Guillem, V. [1 ]
Camp, J. [1 ]
Tortajada, M. I. [1 ]
Gozalbo, F. [1 ]
Vidal, P. [1 ]
Ruiz, A. [1 ]
机构：
[1] Fdn Inst Valenciano Oncol, Valencia, Spain
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70066-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 69
页数：2
相关论文
共 50 条
  • [41] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Onder Tonyali
    Mustafa Benekli
    Veli Berk
    Ugur Coskun
    Metin Ozkan
    Ramazan Yildiz
    Emel Ucgul
    Alper Sevinc
    Dogan Uncu
    Umut Demirci
    Suleyman Buyukberber
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
  • [42] Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy
    Printz, Carrie
    CANCER, 2020, 126 (09) : 1827 - 1827
  • [43] Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer.
    Colomer, R
    Mayordomo, JI
    Calvo, L
    Hornedo, J
    Carabantes, F
    Gil, M
    Martin, B
    Cortes-Funes, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 61S - 61S
  • [44] HER2 ECD-positive metastatic breast cancer treated with gemcitabine, paclitaxel plus trastuzumab (GTH)
    Colomer, R
    Mayordomo, JI
    Calvo, L
    Hornedo, J
    Carabantes, F
    Gil, M
    Cortes-Funes, H
    Martin, B
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S127 - S128
  • [45] Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
    V Guarneri
    A Frassoldati
    F Piacentini
    K Cagossi
    L Cavanna
    A Michelotti
    G Jovic
    S Giovannelli
    G Ficarra
    C Oliva
    P Conte
    Breast Cancer Research, 9
  • [46] Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer
    Theodoulou, Maria
    Batist, Gerald
    Campos, Susana
    Winer, Eric
    Welles, Lauri
    Hudis, Clifford
    CLINICAL BREAST CANCER, 2009, 9 (02) : 101 - 107
  • [47] Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
    Guarneri, V.
    Frassoldati, A.
    Piacentini, F.
    Cagossi, K.
    Cavanna, L.
    Michelotti, A.
    Jovic, G.
    Giovannelli, S.
    Ficarra, G.
    Oliva, C.
    Conte, P.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [48] PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
    Pegram, Mark D.
    Bondarenko, Igor
    Costa Zorzetto, Marina Moreira
    Hingmire, Sachin
    Iwase, Hirotaka
    Krivorotko, Petr V.
    Lee, Keun Seok
    Li, Rubi K.
    Pikiel, Joanna
    Aggarwal, Rajesh
    Ewesuedo, Reginald
    Freyman, Amy
    Li, Ray
    Vana, Alicia
    Yin, Donghua
    Zacharchuk, Charles
    Tan-Chiu, Elizabeth
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 172 - 182
  • [49] PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
    Mark D. Pegram
    Igor Bondarenko
    Marina Moreira Costa Zorzetto
    Sachin Hingmire
    Hirotaka Iwase
    Petr V. Krivorotko
    Keun Seok Lee
    Rubi K. Li
    Joanna Pikiel
    Rajesh Aggarwal
    Reginald Ewesuedo
    Amy Freyman
    Ray Li
    Alicia Vana
    Donghua Yin
    Charles Zacharchuk
    Elizabeth Tan-Chiu
    British Journal of Cancer, 2019, 120 : 172 - 182
  • [50] Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer
    Ogino, Misato
    Fujii, Takaaki
    Koibuchi, Yukio
    Nakazawa, Yuko
    Takata, Daisuke
    Shirabe, Ken
    ANTICANCER RESEARCH, 2021, 41 (08) : 3899 - 3904
12345